Josef Straub

2.1k total citations
18 papers, 708 citations indexed

About

Josef Straub is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Josef Straub has authored 18 papers receiving a total of 708 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Josef Straub's work include Lung Cancer Treatments and Mutations (7 papers), Lung Cancer Research Studies (4 papers) and Hepatocellular Carcinoma Treatment and Prognosis (3 papers). Josef Straub is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Lung Cancer Research Studies (4 papers) and Hepatocellular Carcinoma Treatment and Prognosis (3 papers). Josef Straub collaborates with scholars based in Germany, United States and Belgium. Josef Straub's co-authors include Monika E. Hegi, Isabelle Renard, Katja Bierau, Ilse Vlassenbroeck, Wim Van Criekinge, Walter F. Bodmer, Mohammad Ilyas, Thierry Gorlia, Michael Weller and Burt Nabors and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Josef Straub

18 papers receiving 700 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Josef Straub Germany	11	398	228	169	167	163	18	708
Raquel Longarón Spain	14	224 0.6×	166 0.7×	200 1.2×	242 1.4×	222 1.4×	37	593
Manglio Rizzo Argentina	16	351 0.9×	98 0.4×	103 0.6×	388 2.3×	155 1.0×	44	910
Nadia Coltella Italy	16	387 1.0×	68 0.3×	114 0.7×	194 1.2×	206 1.3×	24	709
Maher N. Younes United States	19	517 1.3×	54 0.2×	158 0.9×	498 3.0×	169 1.0×	21	1.1k
Urszula M. Polanska United Kingdom	15	489 1.2×	93 0.4×	227 1.3×	432 2.6×	209 1.3×	29	884
Maudy Walraven Netherlands	5	326 0.8×	58 0.3×	179 1.1×	287 1.7×	295 1.8×	8	649
Yvonne Parker United States	13	378 0.9×	63 0.3×	142 0.8×	194 1.2×	223 1.4×	24	734
Khatri Latha United States	14	241 0.6×	162 0.7×	70 0.4×	179 1.1×	162 1.0×	20	579
Irina S. Babina United Kingdom	6	575 1.4×	50 0.2×	268 1.6×	386 2.3×	226 1.4×	7	956
Thomas Kryza Australia	16	256 0.6×	143 0.6×	116 0.7×	268 1.6×	160 1.0×	33	657

Countries citing papers authored by Josef Straub

Since Specialization

Citations

This map shows the geographic impact of Josef Straub's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Josef Straub with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Josef Straub more than expected).

Fields of papers citing papers by Josef Straub

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Josef Straub. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Josef Straub. The network helps show where Josef Straub may publish in the future.

Co-authorship network of co-authors of Josef Straub

This figure shows the co-authorship network connecting the top 25 collaborators of Josef Straub. A scholar is included among the top collaborators of Josef Straub based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Josef Straub. Josef Straub is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Ryoo, Baek‐Yeol, Ann‐Lii Cheng, Zhenggang Ren, et al.. (2021). Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression. British Journal of Cancer. 125(2). 200–208. 36 indexed citations

Decaens, Thomas, Carlo Barone, Eric Assénat, et al.. (2021). Correction: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression. British Journal of Cancer. 125(3). 465–465. 2 indexed citations

Decaens, Thomas, C. Barone, Eric Assénat, et al.. (2021). Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression. British Journal of Cancer. 125(2). 190–199. 28 indexed citations

Sakai, Hiroshi, Masahiro Morise, Terufumi Kato, et al.. (2021). Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study. Japanese Journal of Clinical Oncology. 51(8). 1261–1268. 18 indexed citations

Le, Xiuning, Enriqueta Felip, Rémi Veillon, et al.. (2020). Primary efficacy and biomarker analyses from the VISION study of tepotinib in patients (pts) with non-small cell lung cancer (NSCLC) with METex14 skipping.. Journal of Clinical Oncology. 38(15_suppl). 9556–9556. 2 indexed citations

Le, Xiuning, Dariusz M. Kowalski, Byoung Chul Cho, et al.. (2020). Abstract 3385: Liquid biopsy to detect MET exon 14 skipping (METex14) and MET amplification in patients with advanced NSCLC: Biomarker analysis from VISION study. Cancer Research. 80(16_Supplement). 3385–3385. 7 indexed citations

Sakai, Hiroshi, Rémi Veillon, Alexis B. Cortot, et al.. (2019). Tepotinib in NSCLC patients with METex14 mutations: interim results from the phase II VISION study. Annals of Oncology. 30. vi108–vi109. 2 indexed citations

Yang, James Chih‐Hsin, Jianying Zhou, Dong‐Wan Kim, et al.. (2019). Abstract CT193: Tepotinib + gefitinib vs chemotherapy in MET-amplified EGFR-mutant non-small cell lung cancer (NSCLC): Predefined subgroup analysis of a Phase Ib/II study. Cancer Research. 79(13_Supplement). CT193–CT193. 2 indexed citations

Hegi, Monika E., Thierry Gorlia, Roger Stupp, et al.. (2018). MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials. Clinical Cancer Research. 25(6). 1809–1816. 90 indexed citations

10.

Hussain, Maha, Sylvestre Le Moulec, Claude Gimmi, et al.. (2016). Differential Effect on Bone Lesions of Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 22(13). 3192–3200. 48 indexed citations

11.

Weller, Michael, Burt Nabors, Thierry Gorlia, et al.. (2016). Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome. Oncotarget. 7(12). 15018–15032. 63 indexed citations

12.

Renard, Isabelle, Steven Joniau, Ben Van Cleynenbreugel, et al.. (2009). Identification and Validation of the Methylated TWIST1 and NID2 Genes through Real-Time Methylation-Specific Polymerase Chain Reaction Assays for the Noninvasive Detection of Primary Bladder Cancer in Urine Samples. European Urology. 58(1). 96–104. 127 indexed citations

13.

Vlassenbroeck, Ilse, Stèphane Califice, Annie‐Claire Diserens, et al.. (2008). Validation of Real-Time Methylation-Specific PCR to Determine O6-Methylguanine-DNA Methyltransferase Gene Promoter Methylation in Glioma. Journal of Molecular Diagnostics. 10(4). 332–337. 148 indexed citations

14.

Ali, Mamdouh M., Eva Frei, Josef Straub, Andrea Breuer, & Manfred Wießler. (2002). Induction of metallothionein by zinc protects from daunorubicin toxicity in rats. Toxicology. 179(1-2). 85–93. 50 indexed citations

15.

Straub, Josef, Michael Churchman, Walter F. Bodmer, et al.. (2002). Cyclin D1 is not an essential target of beta-catenin signaling during intestinal tumorigenesis, but it may act as a modifier of disease severity in multiple intestinal neoplasia (Min) mice.. PubMed. 62(16). 4562–5. 30 indexed citations

16.

Straub, Josef, et al.. (2001). Alkaline-mediated differential interaction (AMDI): A simple automatable single-nucleotide polymorphism assay. Proceedings of the National Academy of Sciences. 98(5). 2694–2697. 7 indexed citations

17.

Wilkinson, Robert W., Elizabeth Ross, Richard Poulsom, et al.. (2001). Antibody targeting studies in a transgenic murine model of spontaneous colorectal tumors. Proceedings of the National Academy of Sciences. 98(18). 10256–10260. 7 indexed citations

18.

Ilyas, Mohammad, Jason A. Efstathiou, Josef Straub, Hee C. Kim, & Walter F. Bodmer. (1999). Transforming growth factor β stimulation of colorectal cancer cell lines: Type II receptor bypass and changes in adhesion molecule expression. Proceedings of the National Academy of Sciences. 96(6). 3087–3091. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact